ホーム › トリプルネガティブ乳がん › メリーランド州
メリーランド州におけるトリプルネガティブ乳がんの臨床試験
メリーランド州内の拠点で、トリプルネガティブ乳がんに関する18件の研究が参加者を募集しています。
メリーランド州内の都市
公式研究テキスト（英語）
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
- National Institutes of Health Clinical Center, Bethesda
被験者募集中観察研究
18歳〜120歳 · 全性別 · 2026/10/05更新 · NCT07619534A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- MedStar Franklin Square Medical Center ( Site 0031), Baltimore
- MedStar Good Samaritan Hospital ( Site 0079), Baltimore
- MedStar Southern Maryland Hospital Center ( Site 0100), Clinton
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06841354Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Holy Cross Hospital ( Site 0069), Silver Spring
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06393374A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Mercy Medical Center - Baltimore ( Site 0015), Baltimore
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06966700Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT07340541A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- United Theranostics, Glen Burnie
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07020117Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/09更新 · NCT03606967Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Sinai Hospital of Baltimore, Inc., Baltimore
- St. Agnes Hospital, Baltimore
- Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT05633654PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
被験者募集中第2相
18歳以上 · 女性 · 2026/09/03更新 · NCT06245889A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)
- National Institutes of Health Clinical Center, Bethesda
被験者募集中
18歳〜120歳 · 全性別 · 2026/08/21更新 · NCT07067138A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Local Institution - 1035, Baltimore
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/08/10更新 · NCT06926868Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Maryland Oncology Hematology, Rockville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05579366Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Frederick Health Hospital, Frederick
被験者募集中観察研究
18歳以上 · 全性別 · 2026/06/29更新 · NCT07327489Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
- National Institute of Health Clinical Center, Bethesda
被験者募集中第2相
18歳以上 · 全性別 · 2026/06/04更新 · NCT05660083Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
- United Theranostics, Glen Burnie
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/03更新 · NCT07311993A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/11/04更新 · NCT05902988A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
- University of Maryland Medical Center (UMMC), Baltimore
被験者募集中第2相
18歳以上 · 全性別 · 2025/06/19更新 · NCT06568692First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
被験者募集中第1相
18歳以上 · 全性別 · 2022/11/28更新 · NCT05627960ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。